Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-9966
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients ; volume:41 ; number:1 ; day:4 ; month:2 ; year:2022 ; pages:1-17 ; date:12.2022
Journal of experimental & clinical cancer research ; 41, Heft 1 (4.2.2022), 1-17, 12.2022

Creator
Buttarelli, Marianna
Ciucci, Alessandra
Palluzzi, Fernando
Raspaglio, Giuseppina
Marchetti, Claudia
Perrone, Emanuele
Minucci, Angelo
Giacò, Luciano
Fagotti, Anna
Scambia, Giovanni
Gallo, Daniela
Contributor
SpringerLink (Online service)

DOI
10.1186/s13046-022-02265-w
URN
urn:nbn:de:101:1-2022051320320479174479
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Buttarelli, Marianna
  • Ciucci, Alessandra
  • Palluzzi, Fernando
  • Raspaglio, Giuseppina
  • Marchetti, Claudia
  • Perrone, Emanuele
  • Minucci, Angelo
  • Giacò, Luciano
  • Fagotti, Anna
  • Scambia, Giovanni
  • Gallo, Daniela
  • SpringerLink (Online service)

Other Objects (12)

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

First-Line Management of Advanced High-Grade Serous Ovarian Cancer

First-Line Management of Advanced High-Grade Serous Ovarian Cancer

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status

High-grade serous ovarian cancer: the clone wars

High-grade serous ovarian cancer: the clone wars

High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis

High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer

Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer

Principles of dormancy evident in high-grade serous ovarian cancer

Principles of dormancy evident in high-grade serous ovarian cancer

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity

MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma

MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma

No evidence for PALB2 methylation in high-grade serous ovarian cancer

No evidence for PALB2 methylation in high-grade serous ovarian cancer

Related objects